FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to quinazolinone compounds of formula (I) and its pharmaceutically acceptable salts, wherein n is equal to 0 to 3, and R1 is defined as stated in the patent claim. The above compounds are prolyl hydroxylase inhibitors and can be used in pharmaceutical compositions and methods of treating pathological conditions, disorders and conditions mediated by prolyl hydroxylase activity.
EFFECT: compounds can be administered into the patient for treating, eg anaemia, vascular diseases, metabolic disorders, as well as for wound healing.
22 cl, 2 tbl, 211 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | 2009 |
|
RU2531354C2 |
BICYCLIC LACTAMS AND METHODS OF USE THEREOF | 2016 |
|
RU2827714C1 |
INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | 2016 |
|
RU2738232C2 |
HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | 2019 |
|
RU2812128C2 |
MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | 2014 |
|
RU2669393C2 |
SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | 2011 |
|
RU2652638C2 |
Authors
Dates
2014-09-20—Published
2010-02-10—Filed